RegulatoryApr 16, 2026, 04:31 PM
Apimeds Pharmaceuticals Expects Late 10-K Filing, Faces NYSE Non-Compliance
AI Summary
Apimeds Pharmaceuticals US, Inc. announced it will not file its 2025 Annual Report on Form 10-K within the extended deadline, citing ongoing financial statement preparation and audit completion. This delay is expected to lead to a notice from NYSE American regarding non-compliance with continued listing requirements. The company is working diligently and aims to file the Form 10-K by April 30, 2026, though this timeline is not guaranteed.
Key Highlights
- Filed Form 12b-25 on March 31, 2026, for late 2025 Form 10-K.
- Expects to miss the 15-day extension period for filing its 2025 Form 10-K.
- Anticipates receiving a non-compliance notice from NYSE American.
- Aims to file the Form 10-K by April 30, 2026, but without assurance.